Sort by
Immunology and Microbiology
Cyclophosphamide
100%
Graft-Versus-Host Disease
63%
Transplant Procedure
51%
Bone Marrow Transplantation
45%
Conditioning
31%
T Cell
30%
Drug Megadose
27%
Overall Survival
24%
Human Leukocyte Antigen
16%
Hematopoietic Cell
15%
Cell Transplantation
14%
Chronic Graft Versus Host Disease
14%
Lymphocyte
13%
Engraftment
13%
Progression Free Survival
13%
Acute Graft Versus Host Disease
13%
Umbilical Cord Blood
13%
Myeloid
12%
Stem Cell Transplantation
11%
Chimera
11%
Recurrence Free Survival
8%
Allogeneic Bone Marrow Transplantation
8%
Allotransplantation
8%
Event Free Survival
7%
Immunosuppression
7%
Cord Blood Stem Cell Transplantation
6%
Allotransplantation
6%
Hematopoietic Stem Cell Transplantation
6%
Mouse
6%
Sickle Cell
5%
Aplastic Anemia
5%
B Cell
5%
Mycophenolic Acid
5%
Alloimmunity
5%
Keyphrases
Post-transplantation Cyclophosphamide (PTCy)
66%
Graft-versus-host Disease (GvHD)
44%
Haploidentical Transplantation
37%
HLA-haploidentical
26%
Nonmyeloablative
18%
Hematological Malignancies
17%
Confidence Interval
17%
HLA Matching
17%
Haploidentical
17%
Allogeneic Blood or Marrow Transplantation
15%
Transplantation
14%
Overall Survival
14%
Human Leukocyte Antigen
13%
Graft-versus-host Disease Prophylaxis
13%
Bone Marrow Transplantation
13%
Blood or Marrow Transplantation
13%
Allogeneic Bone Marrow Transplantation
13%
Haploidentical Donor
13%
High Dose
11%
Reduced-intensity Conditioning
11%
Hazard Ratio
11%
Non-relapse Mortality
10%
Marrow Transplantation
9%
Allogeneic Transplantation
9%
Unrelated Donor
9%
Donor Lymphocyte Infusion
9%
Cyclophosphamide
7%
Cumulative Incidence
7%
Myeloablative Conditioning
7%
Myeloablative
7%
Bone Marrow
7%
HLA-matched Donor
6%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
6%
Progression-free Survival
6%
Acute Myeloid Leukemia
6%
Pretransplant
6%
Event-free Survival
6%
Haploidentical Hematopoietic Stem Cell Transplantation
6%
Mismatched Related Donor
6%
Graft Failure
5%
High-dose Cyclophosphamide
5%
High Risk
5%
Severe Aplastic Anemia
5%
Immunosuppression
5%
Acute Leukemia
5%
Peripheral Blood
5%
Relapse-free Survival
5%
Acute Lymphoblastic Leukemia
5%
Medicine and Dentistry
Cyclophosphamide
48%
Graft Versus Host Reaction
33%
Transplantation
22%
Bone Marrow Transplantation
21%
T Cell
20%
Hematologic Malignancy
16%
Disease
14%
Prophylaxis
13%
Overall Survival
13%
Drug Megadose
12%
Cumulative Incidence
9%
Donor Lymphocyte Infusion
8%
Acute Myeloid Leukemia
8%
Graft Failure
8%
Chronic Graft Versus Host Disease
7%
Nonmyeloablative Conditioning
7%
Allogenic Bone Marrow Transplantation
7%
Cell Transplantation
7%
Malignant Neoplasm
7%
Whole Body Radiation
6%
Progression Free Survival
6%
Immunotherapy
6%
Event Free Survival
6%
Immunosuppressive Treatment
6%
Stem Cell Therapy
5%
Acute Graft Versus Host Disease
5%
Hazard Ratio
5%
Hematopoietic Stem Cell
5%
Engraftment
5%